Supplements and Featured Publications

The 2021 ASH Annual Meeting: CAR T-Cell Therapy priority report is a digital version of the print publication spanning some of the groundbreaking abstracts in CAR T-cell therapy that were presented during the conference.

The 2021 Year in Review: HER2+ Breast Cancer is the digital version of a print publication encompasses some of the biggest data that have read out in HER2-positive breast cancer in 2021, along with expert insights in article and video format.

The My Treatment Approach: Advanced Ovarian Cancer publication covers some of the latest practice-changing advances in the treatment for patients with advanced ovarian cancer following recent regulatory decisions and data read outs from pivotal clinical trials, as well as expert insights on how they approach therapy on an individualized basis.

The 2021 Year in Review: Updates in Biomarker-Driven Lung Cancer is the digital version of a print publication encompasses some of the biggest data that have read out in bimarker-driven lung cancer in 2021, along with expert insights in article and video format.

Funding From Daiichi Sankyo/Content Developed Independently by OncLive

The My Treatment Approach: Optimal Second- and Third-Line Treatment Options of cGVHD publication covers some of the latest and practice-changing advances in the treatment for patients with chronic graft-vs-host disease following recent regulatory decisions and data read outs from pivotal clinical trials, as well as expert insights on how they approach therapy on an individualized basis.

The 2021 ESMO Congress priority report focuses on updates in genitourinary cancers presented at the virtual conference, held September 16 to 21, 2021.

The 2021 ESMO Congress priority report focuses on updates in breast cancer presented at the virtual conference, which was held September 16 to 21, 2021.

This publication spans multiple updates regarding systemic treatment for patients with myelofibrosis, as well as expert insights in video format covering how they approach their patients with newly available agents.

This publication covers some of the latest advances in colorectal cancer treatment following recent read outs from clinical trials, as well as expert insights on how they approach therapy on an individualized basis.

This publication features research that was presented in myelodysplastic syndromes from the 2021 ASCO Annual Meeting and 2021 EHA Congress, including expert perspectives on how the data have clinical implications.

Sponsored by Takeda Oncology/Content Developed Independently by OncLive

This publication covers a multitude of presentations in myeloproliferative neoplasms that were presented and discussed during the 2021 ASCO Annual Meeting.

This publication provides coverage of data in genitourinary cancers that were presented at the 2021 ASCO Annual Meeting.

Coverage of the 2021 EBMT Annual Meeting, held virtually March 14-17, 2021.